MediWound (MDWD) announced the successful completion of the commissioning process for its expanded GMP manufacturing facility in Yavne, Israel. This milestone represents an important positive development toward full operational readiness and expanding the Company’s capacity to meet rising global demand for NexoBrid. The expanded facility, which is expected to achieve full operational readiness by year-end 2025, will increase production capacity for NexoBrid by approximately sixfold, enabling scalable, reliable supply to meet the product’s growing global demand. Market availability remains subject to the completion of regulatory reviews.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDWD:
- MediWound’s EscharEx Study: A Potential Game-Changer for Venous Leg Ulcers
- MediWound’s New Study on EscharEx: A Potential Game-Changer for Venous Leg Ulcers
- MediWound Raises $30 Million Through Share Offering to Boost EscharEx® Initiatives
- MediWound Announces $30 Million Direct Offering to Boost Operations
- MediWound announces $30M registered direct offering